Vnitr Lek 2012, 58(10):785-801

Diagnosis and treatment of arterial hypertension. 2012 Guidelines of the Czech Hypertension Society

J. Filipovský1,*, J. Widimský jr2, J. Ceral3, R. Cífková4, K. Horký5, A. Linhart5, V. Monhart6, H. Rosolová1, J. Seidlerová1, M. Souček7, J. ©pinar8, J. Vítovec9, J. Widimský10
1 II. interní klinika Lékařské fakulty UK a FN Plzeň, přednosta prof. MUDr. Jan Filipovský, CSc.
2 III. interní klinika 1. lékařské fakulty UK a VFN Praha, přednosta prof. MUDr. ©těpán Svačina, DrSc., MBA
3 I. interní kardioangiologická klinika Lékařské fakulty UK a FN Hradec Králové, přednosta prof. MUDr. Jan Vojáček, DrSc., FESC, FACC
4 Centrum kardiovaskulární prevence 1. lékařské fakulty UK a Thomayerovy nemocnice Praha, vedoucí centra prof. MUDr. Renata Cífková, CSc.
5 II. interní klinika - klinika kardiologie a angiologie 1. lékařské fakulty UK a VFN Praha, přednosta prof. MUDr. Aleą Linhart, DrSc., FESC
6 Interní klinika 1. lékařské fakulty UK a ÚVN Praha, přednosta prof. MUDr. Miroslav Zavoral, Ph.D.
7 II. interní klinika Lékařské fakulty MU a FN u sv. Anny Brno, přednosta prof. MUDr. Miroslav Souček, CSc.
8 Interní kardiologická klinika Lékařské fakulty MU a FN Brno, pracoviątě Bohunice, přednosta prof. MUDr. Jindřich ©pinar, CSc., FESC
9 I. interní kardio-angiologická klinika Lékařské fakulty MU a FN u sv. Anny Brno, přednosta prof. MUDr. Jiří Vítovec, CSc., FESC
10 Klinika kardiologie Institutu klinické a experimentální medicíny Praha, přednosta prof. MUDr Jan Kautzner, CSc., FESC

Received: August 6, 2012; Published: October 1, 2012  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Filipovský J, Widimský J, Ceral J, Cífková R, Horký K, Linhart A, et al.. Diagnosis and treatment of arterial hypertension. 2012 Guidelines of the Czech Hypertension Society. Vnitr Lek. 2012;58(10):785-801.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Widimský J Jr, Cífková R, ©pinar J et al. Doporučení diagnostických a léčebných postupů u arteriální hypertenze - verze 2007. Vnitř Lék 2008; 54: 101-118. Go to PubMed...
    2. Mancia G, De Backer G, Dominiczak A et al. 2007 Guidelines for the Management of Arterial Hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension and of the European Society of Cardiology (ESC). J Hypertens 2007; 25: 1105-1187. Go to original source... Go to PubMed...
    3. Mancia G, Laurent S, Agabiti-Rosei E et al. Reappraisal of European guidelines on hypertension management: a European Society of Hypertension Task Force document. J Hypertens 2009; 27: 2121-2158. Go to original source... Go to PubMed...
    4. Cífková R, Bruthans J, Adámková V et al. Prevalence základních kardiovaskulárních rizikových faktorů v české populaci v letech 2006-2009. Studie Czech post-MONICA. Cor Vasa 2011; 53: 220-229. Go to original source...
    5. Funder JW, Carey RM, Fardella C et al. Case detection, diagnosis and treatment of patients with primary aldosteronism: an endocrine society clinical practice guideline. J Clin Endocrinol Metab 2008; 93: 3266-3281. Go to original source... Go to PubMed...
    6. Reference Values for Arterial Stiffness' Collaboration. Determinants of pulse wave velocity in healthy people and in the presence of cardiovascular risk factors: "establishing normal and reference values". Eur Heart J 2010; 19: 2338-2350.
    7. Wald DS, Law M, Morris JK et al. Combination therapy versus monotherapy in reducing blood pressure: meta-analysis on 11,000 participants from 42 trials. Am J Med 2009; 122: 290-300. Go to original source... Go to PubMed...
    8. Messerli FH, Makani H, Benjo A et al. Antihypertensive efficacy of hydrochlorothiazide as evaluated by ambulatory blood pressure monitoring: a meta-analysis of randomized trials. J Am Coll Cardiol 2011; 57: 590-600. Go to original source... Go to PubMed...
    9. Dorsch MP, Gillespie BW, Erickson SR et al. Chlorthalidone reduces cardiovascular events compared with hydrochlorothiazide: a retrospective cohort analysis. Hypertension 2011; 57: 689-694. Go to original source... Go to PubMed...
    10. Vaclavik J, Sedlak R, Plachy M et al. Addition of spironolactone in patients with resistant arterial hypertension (ASPIRANT): a randomized, double-blind, placebo-controlled trial. Hypertension 2011; 57: 1069-1075. Go to original source... Go to PubMed...
    11. Wright JM, Musini VM. First-line drugs for hypertension. Cochrane Database Syst Rev 2009; 3: CD001841. Go to original source...
    12. Jamerson K, Weber MA, Bakris GL et al. Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patients. N Engl J Med 2008; 359: 2417-2428. Go to original source... Go to PubMed...
    13. Matsuzaki M, Ogihara T, Umemoto S et al. Combination Therapy of Hypertension to Prevent Cardiovascular Events Trial Group. Prevention of cardiovascular events with calcium channel blocker-based combination therapies in patients with hypertension: a randomized controlled trial. J Hypertens 2011; 29: 1649-1659. Go to original source... Go to PubMed...
    14. Yusuf S, Teo KK, Pogue J et al. ONTARGET Investigators. Telmisartan, ramipril or both in patients at high risk for vascular events. N Engl J Med 2008; 358: 1547-1559. Go to original source... Go to PubMed...
    15. Beckett NS, Peters R, Fletcher AE et al. HYVET Study Group. Treatment of hypertension in patients 80 years of age or older. N Engl J Med 2008; 358: 1887-1898. Go to original source... Go to PubMed...
    16. Cushman WC, Evans GW, Byingtom RP et al. ACCORD Study Group. Effects of intensive blood-pressure control in type 2 diabetes mellitus. N Engl J Med 2010; 362: 1575-1585. Go to original source... Go to PubMed...
    17. Scheffers IJ, Kroon AA, Schmidli J et al. Novel baroreflex activation therapy in resistant hypertension: results of a European multi-center feasibility study. J Am Coll Cardiol 2010; 56: 1254-1258. Go to original source... Go to PubMed...
    18. Esler MD, Krum H, Sobotka PA et al. Renal sympathetic denervation in patients with treatment-resistant hypertension (The Symplicity HTN-2 Trial): a randomised controlled trial. Lancet 2010; 376: 1903-1909. Go to original source... Go to PubMed...
    19. Widimský P, Filipovský J, Widimský J Jr et al. Odborné stanovisko České kardiologické společnosti a české společnosti pro hypertenzi k provádění katetrizačních renálních denervací (RDN) v České republice. Cor Vasa 2012; 54: 155-159. Go to original source...
    20. Leddy MA, Power ML, Schulkin J. The impact of maternal obesity on maternal and fetal health. Rev Obstet Gynecol 2008; 1: 170-178.
    21. Bujold E, Roberge S, Lacasse Y et al. Prevention of preeclampsia and intrauterine growth restriction with aspirin started in early pregnancy: a meta-analysis. Obstet Gynecol 2010; 116: 402-414. Go to original source... Go to PubMed...
    22. McDonald SD, Malinowski A, Zhou Q et al. Cardiovascular sequelae of preeclampsia/eclampsia: a systematic review and meta-analyses. Am Heart J 2008; 156: 918-930. Go to original source... Go to PubMed...
    23. Vaverková H, Soąka V, Rosolová H et al. Doporučení pro diagnostiku a léčbu dyslipidemií v dospělosti, vypracované výborem České společnosti pro aterosklerózu. Cor Vasa 2007; 49: K73-K86.

    Return to the content


    Vnitřní lékařství

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.